Iheezo FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 29, 2022.
FDA Approved: Yes (First approved September 27, 2022)
Brand name: Iheezo
Generic name: chloroprocaine hydrochloride
Dosage form: Ophthalmic Gel
Company: Harrow
Treatment for: Ocular Surface Anesthesia
Iheezo (chloroprocaine hydrochloride) is an ester anesthetic indicated for ocular surface anesthesia.
- Iheezo is the first ophthalmic formulation of chloroprocaine hydrochloride, an anesthetic previously approved in injectable formulations under the brand names Nesacaine/Nesacaine-MPF for local anesthesia and Clorotekal for spinal anesthesia.
- Iheezo is physician‑administered topically to the ocular surface prior to the planned surgical procedure.
- Iheezo is rapidly acting (about 1 to 1.5 minutes) and the anesthetic effect lasts around 20 minutes.
- The most common adverse reaction is mydriasis.
Development timeline for Iheezo
| Date | Article |
|---|---|
| Sep 27, 2022 | Approval FDA Approves Iheezo (chloroprocaine hydrochloride ophthalmic gel) for Ocular Surface Anesthesia |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
